Ipamorelin

Summary

Ipamorelin is a synthetic peptide that acts as a growth‑hormone secretagogue (GHS) by stimulating the ghrelin receptor. It is investigated primarily as an adjunct for musculoskeletal repair, body‑composition modulation, and age‑related tissue decline, but it remains a research‑only compound without regulatory approval for clinical use.

Mechanism of Action

Ipamorelin binds to the ghrelin (GHS‑R) receptor on pituitary somatotrophs, triggering intracellular signaling that culminates in the release of growth hormone (GH). The surge in GH raises circulating insulin‑like growth factor‑1 (IGF‑1), which activates downstream pathways such as PI3K/Akt, mTOR, MAPK, and AMPK, supporting protein synthesis, satellite‑cell activation, and tissue repair.

What the Research Shows

Pre‑clinical and early‑phase human data dominate the literature. A 1999 PK/PD trial in healthy men showed dose‑proportional pharmacokinetics, a 2‑hour half‑life, and a single, dose‑dependent GH pulse peaking at ~0.7 h. Animal studies reported that ipamorelin combined with CJC‑1295 improved tetanic muscle tension in glucocorticoid‑induced atrophy. Orthopaedic reviews cite its activation of IGF‑1 signaling and satellite‑cell repair, while gerontology and andrology reviews suggest potential for body‑composition improvement and age‑related tissue maintenance. Across all sources, human efficacy data for musculoskeletal injury, performance, or aging are lacking.

Reported Benefits

The peptide reliably induces a transient GH surge in humans, which in theory can promote protein synthesis, muscle mass preservation, and tissue regeneration. Animal models suggest enhanced muscle force recovery and possible synergistic effects when paired with other GHSs. These mechanistic benefits underpin interest in orthopaedic, sports‑medicine, and anti‑aging contexts.

Limitations of the Evidence

No randomized clinical trials have demonstrated therapeutic benefit in humans for any indication. Evidence is limited to a single PK/PD study and several animal experiments. The variability in pharmacodynamic response is greater than pharmacokinetic variability, indicating unpredictable GH output. Long‑term safety, optimal dosing, and efficacy remain uncharacterized, and regulatory approval has not been granted.

Safety Considerations

The 1999 human study reported GH release without detailing adverse events, suggesting short‑term tolerability at the investigated doses. However, reviews repeatedly note the paucity of systematic safety data, especially for chronic or repeated administration. Potential concerns include excessive GH/IGF‑1 exposure, metabolic effects, and unknown immunogenicity. Caution is advised until rigorous safety evaluations are completed.

How It Is Administered

Ipamorelin is administered as a peptide solution via intravenous infusion, subcutaneous injection, or intranasal delivery. The PK study used short IV infusions; other reports mention subcutaneous dosing. Formulations are typically sterile aqueous solutions intended for research purposes only.

Routes of Administration

Goals & Uses

• Increase endogenous growth hormoneEndocrineModerate
• Enhance recovery after exercisePerformanceLow
• Body Composition Improvement (Lean Mass / Fat Loss)Metabolic / Body CompositionLow
• Improve body compositionMusculoskeletalLow
• Recovery and Tissue RepairRegenerative / RecoveryLow
• Increased Growth Hormone SecretionEndocrine / HormonalModerate
• Sleep Quality ImprovementNeurological / SleepLow
• Anti-aging / LongevityAgingLow
• Bone Density MaintenanceMusculoskeletalLow

Contraindications

• Active malignancyOncologyHighUse caution or avoid depending on agent and context
• PregnancyPopulationHighPotential fetal risk or insufficient safety data
• Diabetic retinopathyOphthalmologyHigh
• Uncontrolled Diabetes MellitusMetabolic / EndocrineModerate
• LactationReproductiveHigh
• Pituitary Tumor or Hypothalamic DiseaseNeurological / EndocrineHigh

Adverse Effects

• Injection site reactionsLocalCommon
• Injection site painLocalCommonPain at the injection site
• HeadacheNeurologicUncommonPain in the head or upper neck
• Water retention / edemaFluid BalanceCommon
• FlushingVascularCommonWarmth and redness of the skin
• Transient hyperglycemiaMetabolic/EndocrineRare
• Transient HypoglycemiaMetabolicUncommon
• Elevated IGF-1EndocrineCommon
• DizzinessNeurologicUncommonFeeling faint, lightheaded, or unsteady

Drug Interactions

• Other GH secretagogues (e.g., GHRP‑2, GHRP‑6)Moderate
• InsulinModerateMay increase risk of low blood sugar
• Insulin / antidiabetic agentsModerate
• CJC-1295 / GHRH AnaloguesModerate
• CorticosteroidsLow
• Thyroid hormone replacementLow

Population Constraints

• Elderly (>65 years)AgeRelative
• Pediatric patientsAgeRelative
• Pediatrics (<18 years)AgeRelative
• Lactating IndividualsReproductiveAbsolute
• Patients with history of cancerOncologyRelative
• Patients with Insulin Resistance or Type 2 DiabetesMetabolicRelative

Regulatory Status

• European UnionUnapprovedNo marketing authorization; classified as a research chemical
• United StatesInvestigationalNot FDA‑approved; available only for research use
• United KingdomUnapprovedNot licensed for medicinal use; sold for laboratory research only

Not approved by the FDA, EMA, or other major regulatory agencies for human therapeutic use. In 2023–2024, the FDA moved to restrict compounding of ipamorelin/CJC-1295 combinations. It remains classified as a research compound. Frequently used off-label in anti-aging and performance medicine clinics via compounding pharmacies.

Evidence & Sources

• Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions
  Journal ArticleModerateRahman OF, Lee SJ, Seeds WA2026-01-01T00:00:00.000000Z
• Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians
  Journal ArticleModerateMayfield CK, et al.2026-01-01T00:00:00.000000Z
• Therapeutic peptides in gerontology: mechanisms and applications for healthy aging
  Journal ArticleModerateMavrych V, Shypilova I, Bolgova O2026-01-01T00:00:00.000000Z
• Beyond the androgen receptor: the role of growth hormone secretagogues in the modern management of body composition in hypogonadal males
  Journal ArticleModerateSinha DK, et al.2020-01-01T00:00:00.000000Z
• Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance
  Journal ArticleModerateMendias CL, Awan TM2026-01-01T00:00:00.000000Z
• Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers
  Journal ArticleModerateGobburu JV, et al.1999-01-01T00:00:00.000000Z

Frequently Asked Questions